Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7255 results

Sort By:

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Study ID: NCT06784726
Start Date: 2025-07-15
End Date: 2033-04-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

27

Intervention / Treatment

Odronextamab

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Chimeric Antigen Receptor T-Cell Therapy

Computed Tomography

Leukapheresis

Lumbar Puncture

Positron Emission Tomography

Administration questionnaire

Biopsy

Sponsor

University of Washington

Source: clinicaltrials.gov

Share:
Add to list

Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention

Study ID: NCT06982066
Start Date: 2025-02-10
End Date: 2029-06-29
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

ReSPECT

Sponsor

Connecticut Children's Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Study ID: NCT05592626
Start Date: 2023-01-04
End Date: 2026-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

365

Intervention / Treatment

Star ౦౬౦౨

Sponsor

Marengo Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Addressing Genomic Disparities in Cancer Survivors

Study ID: NCT06073626
Start Date: 2024-07-31
End Date: 2027-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

428

Intervention / Treatment

Relational agent (RA) / Chatbot

Enhanced Usual Care (EUC)

Sponsor

Rutgers, The State University of New Jersey

Source: clinicaltrials.gov

Share:
Add to list

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

Study ID: NCT06834126
Start Date: 2025-04-07
End Date: 2028-09-19
Study Type

Interventional

Study Phase

Phase1

No. of Participants

36

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Consolidation Therapy

Functional Magnetic Resonance Imaging

Gastrointestinal Endoscopy

Magnetic Resonance Imaging

Papaverine

Radiation Therapy

Total Mesorectal Excision

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Study ID: NCT06146257
Start Date: 2024-01-11
End Date: 2026-10-08
Study Type

Interventional

Study Phase

Phase1

No. of Participants

48

Intervention / Treatment

GLB-001

Sponsor

GluBio Therapeutics Inc.

Source: clinicaltrials.gov

Share:
Add to list

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Study ID: NCT04634357
Start Date: 2022-07-19
End Date: 2028-01-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

15

Intervention / Treatment

ET140203 T Cells

Sponsor

Eureka Therapeutics Inc.

Source: clinicaltrials.gov

Share:
Add to list

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

Study ID: NCT05056857
Start Date: 2021-10-01
End Date: 2026-10-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

290

Intervention / Treatment

Biospecimen Collection

Electronic Health Record Review

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Study ID: NCT06789757
Start Date: 2025-02-25
End Date: 2027-01-27
Study Type

Interventional

Study Phase

Phase2

No. of Participants

19

Intervention / Treatment

Memantine Hydrochloride

Infinite

Atezolizumab

Sponsor

Inova Health Care Services

Source: clinicaltrials.gov

Share:
Add to list

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Study ID: NCT06649812
Start Date: 2026-03-21
End Date: 2027-09-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

120

Intervention / Treatment

Biopsy Procedure

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Computed Tomography

Ibrutinib

Lenalidomide

Magnetic Resonance Imaging

Obinutuzumab

Positron Emission Tomography

Prednisone

Venetoclax

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list